JOHANNESBURG (Reuters) - The African Union's disease control body said on Thursday that it was not "walking away" from AstraZeneca's COVID-19 vaccine, after trial data showed it had greatly reduced efficacy against the coronavirus variant dominant in South Africa.
African countries are due to receive 100 million doses of the AstraZeneca shot this year under an AU vaccine plan.
